Canine Parvovirus Nanobody CPV-VHH-E3 Specific Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for canine parvovirus (CPV) face challenges due to rapid virus mutation, weak cross-protection, and biosafety risks associated with live attenuated vaccines, necessitating the development of more effective and safer immunological tools.
Innovation Solution
A canine parvovirus nanobody, CPV-VHH-E3, is constructed using phage-display technology and expressed through a mammalian cell system, providing specific binding to CPV and potential applications in diagnosis and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If live attenuated vaccines are used for CPV prevention, then immune protection is excellent, but biosafety risks increase due to spreading and returning virulence
Solution Approach 1:
The patent extracts only the essential protective function from live attenuated vaccines by using nanobodies that specifically bind to CPV antigens. This provides immune protection without the biosafety risks of live virus components, effectively separating the beneficial immune response from the harmful virulence risks.
Solution Approach 2:
The patent creates a simplified copy of the immune protection mechanism using nanobodies that mimic the function of natural antibodies. These nanobodies replicate the protective effect against CPV without requiring live virus components, thereby eliminating biosafety concerns while maintaining excellent immune protection.
2Duration of action of stationary object
If live attenuated vaccines are used for CPV prevention, then duration of immunity is long, but cross-protection against mutant strains is weak
Solution Approach 1:
The patent applies local quality by designing nanobodies with highly specific binding characteristics tailored to conserved regions of CPV. This localized specificity ensures both long-lasting immunity and broad cross-protection against mutant strains, as the nanobodies target essential viral structures that remain unchanged across different CPV variants.
Solution Approach 2:
The patent achieves universality by developing nanobodies that can recognize and bind to multiple CPV strain variants. These nanobodies possess multi-functional capabilities, providing both prolonged immunity and broad cross-protection against heterologous viruses, thereby resolving the contradiction between duration and adaptability.
3Reliability
If vaccination is used for CPV prevention, then disease control is effective, but difficulty increases due to rapid virus mutation and pathogenicity changes
Solution Approach 1:
The patent replaces the complex mechanical system of live virus attenuation and stabilization with a simpler molecular approach using nanobodies. This substitution eliminates the need for complex vaccine development processes while maintaining effective disease control, as nanobodies can be produced through straightforward recombinant technology without requiring virus cultivation and attenuation.
Data Source
AI summary
Provided are a canine parvovirus (CPV) nanobody CPV-VHH-E3 and application thereof, belonging to the technical field of immunology. The nanobody CPV-VHH-E3 includes heavy chain variable region with amino acid sequence as shown in SEQ ID NO: 1, and a nucleotide sequence of a gene encoding the nanobody CPV-VHH-E3 is shown in SEQ ID NO: 2. The present application constructs a nanobody immune library for CPV by phage-display technology, and obtains specific anti-CPV nanobody CPV-VHH-E3 by screening, which is verified to specifically bind CPV through experiments, and is applicable to develop a nanobody preparation for clinical diagnosis and treatment of CPV, providing a certain theoretical support for the application of nanobodies in the field of veterinary biological products.